FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.885,93 -1.332,25 (-2,21%)
MeiraGTx Holdings plc (MGTX)
Dopo ore:
| Chiusura precedente | 4,7100 |
| Aperto | 4,7400 |
| Denaro | 4,7500 x 100 |
| Lettera | 4,8400 x 100 |
| Min-Max giorno | 4,6800 - 4,8600 |
| Intervallo di 52 settimane | 3,4900 - 8,3500 |
| Volume | |
| Media Volume | 147.663 |
| Capitalizzazione | 308,243M |
| Beta (5 anni mensile) | 1,27 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,4900 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 21,60 |
GlobeNewswireMeiraGTx Reports Second Quarter 2023 Financial and Operational Results
Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12
- GlobeNewswire
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapyLONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncology, which is being held from August 1-2, 2023, in Seattle, WA. “We are pleased
- GlobeNewswire
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
LONDON and NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection by the Irish Health Products Regulatory Authority (HPRA), it has received a Commercial Manufacturer’s/Importer’s Authorization (MIA) for its Quality Control (QC) testing facility at its GMP manufacturing site in Shannon, Ireland. “Receiving our first commercial license for our state-of-the-art
